Drug Shortage Report for MORPHINE SULFATE INJECTION, USP
| Report ID | 243494 |
| Drug Identification Number | 02482681 |
| Brand name | MORPHINE SULFATE INJECTION, USP |
| Common or Proper name | MORPHINE SULFATE INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | MORPHINE SULFATE |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | 1 mL |
| ATC code | N02AA |
| ATC description | OPIOIDS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2024-12-01 |
| Actual start date | |
| Estimated end date | 2025-01-06 |
| Actual end date | 2025-01-06 |
| Shortage status | Resolved |
| Updated date | 2025-01-08 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Morphine Sulfate Injection, USP 2 mg / mL SD Vial 1 mL effective December 1, 2024, until January 6, 2025. Please note that all current inventory is short-dated and expiring November 30, 2024 |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2025-01-08 | French | Compare |
| v4 | 2025-01-08 | English | Compare |
| v3 | 2024-12-02 | English | Compare |
| v2 | 2024-11-20 | French | Compare |
| v1 | 2024-11-20 | English | Compare |
Showing 1 to 5 of 5